Mostrando 1 - 2 Resultados de 2 Para Buscar 'Boyle, F', tiempo de consulta: 0.11s Limitar resultados
1
artículo
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Allia...
Publicado por
de, Azambuja, E, Piccart-Gebhart, M, Fielding, S, Townend, J, Hillman, DW, Colleoni, M, Roylance, R, Kelly, CM, Lombard, J, El-Abed, S, Choudhury, A, Korde, L, Vicente, M, Chumsri, S, Rodeheffer, R, Ellard, SL, Wolff, AC, Holtschmidt, J, Lang, I, Untch, M, Boyle, F, Xu, B, Werutsky, G, Tujakowski, J, Huang, C-S, Baruch, NB, Bliss, J, Ferro, A, Gralow, J, Kim, S-B, Kroep, JR, Krop, I, Kuemmel, S, McConnell, R, Moscetti, L, Knop, AS, van, Duijnhoven, F, Gomez, H, Cameron, D, Di, Cosimo, S, Gelber, RD, Moreno-Aspitia, A
Publicado 2024 Enlace
Background: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis of the ALTTO trial. Patients and methods: The ALTTO trial (NCT00490139) is a prospective randomized, phase III, open-label, multicenter study that investigated the role of adjuvant chemotherapy and trastuzumab alone, in combination or sequentially with lapatinib. The primary endpoint was disease-free survival (DFS) and secondary endpoints included overall survival (OS), time to distant recurrence and safety. Results: Overall, 6281 patients with HER2-positive early breast cancer were included in the final efficacy analysis in three treatment groups: trastuzumab (T), lapatinib + trastuzumab (L + T) and trastuzumab followed by lapatinib (T→L). Baseline characteristics were well...
Agregar a favoritos
Guardado en:
2
artículo
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Publicado por
Cardoso, F, Paluch-Shimon, S, Senkus, E, Curigliano, G, Aapro, MS, André, F, Barrios, CH, Bergh, J, Bhattacharyya, GS, Biganzoli, L, Boyle, F, Cardoso, MJ, Carey, LA, Cortés, J, El Saghir, NS, Elzayat, M, Eniu, A, Fallowfield, L, Francis, PA, Gelmon, K, Gligorov, J, Haidinger, R, Harbeck, N, Hu, X, Kaufman, B, Kaur, R, Kiely, BE, Kim, SB, Lin, NU, Mertz, SA, Neciosup, SO, ffersen, BV, Ohno, S, Pagani, O, Prat, A, Penault-Llorca, F, Rugo, HS, Sledge, GW, Thomssen, C, Vorobiof, DA, Wiseman ,T, Xu, B, Norton, L, Costa, A, Winer, EP
Publicado 2020 Enlace
This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients. It provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care. Updated diagnostic and treatment algorithms are also provided. All recommendations were compiled by a multidisciplinary group of international experts. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.
Agregar a favoritos
Guardado en: